Guest Editors
Dr. Zhijia Xia
Email: zhijia_xia@yeah.net
Affiliation: Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, D-81377 Munich, Germany
Homepage:
Research Interests: cancer, immunity, bioinformatics
Dr. Jing Zhang
Email: jing.zhang@coyotes.usd.edu
Affiliation: Division of Basic Biomedical Sciences, The University of South Dakota Sanford School of Medicine, Vermillion, South Dakota, 57069, USA
Homepage:
Research Interests: cancer, immune cell, inflammatory diseases
Summary
The tumor microenvironment (TME) plays a critical role in the progression, metastasis, and therapeutic resistance of solid tumors. As tumors develop, they interact with immune cells, stromal components, and vasculature, creating a complex network that influences treatment responses. Early detection through biomarkers is essential to improving the prognosis and survival of patients, yet current methods for early screening remain inadequate.
Advancements in treatment strategies for solid tumors, including targeted therapies and immunotherapies, have shown promise but are often hindered by limitations such as resistance, heterogeneity, and off-target effects. Multi-target combination therapies are increasingly explored as a way to overcome these challenges. To improve the effectiveness of these treatments, there is a pressing need to identify novel biomarkers that can aid in the early diagnosis, prognosis, and therapeutic targeting of tumors.
Volume I has achieved tremendous success, attracting active participation from scientists worldwide and resulting in the publication of several significant papers. Volume II of this special issue continues to focus on emerging biomarkers associated with immune responses, such as novel immune checkpoint targets and immune cell-related biomarkers, as well as those related to the sensitivity to radiation and chemotherapy. The identification of such biomarkers could lead to more personalized and effective treatment regimens, enhancing the management of solid tumors and improving patient outcomes.
Potential topics include but are not limited to the following:
1. Emerging biomarkers for the prediction of immunotherapy and chemotherapy adverse events
2. Novel diagnostic and prognostic biomarkers for solid tumors.
3. Artificial intelligence (AI) -driven therapeutics: Innovations in cancer management
4. Recent advances in the field of novel chemotherapeutic agents, including nanotechnology and targeted therapeutics.
5. The association between the immune microenvironment and cancer development.
6. Utilization of circulating tumor DNA and microRNA for the diagnosis and prognostic evaluation of solid tumors.
7. Exploration of factors influencing tumor progression through mendelian randomization analysis.
Keywords
Tumor Microenvironment, Biomarkers, Immunotherapy, Early Diagnosis, Chemotherapy Sensitivity, Immune Checkpoints
Login
Register
Submit a Paper
Propose a Special lssue